Stock Yards Bank & Trust Co. Lowers Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stock Yards Bank & Trust Co. cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,777 shares of the medical research company’s stock after selling 146 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Thermo Fisher Scientific were worth $3,597,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in TMO. International Assets Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 43.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,626 shares of the medical research company’s stock worth $810,000 after purchasing an additional 493 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in Thermo Fisher Scientific by 33.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 896 shares of the medical research company’s stock worth $454,000 after purchasing an additional 224 shares in the last quarter. Wedge Capital Management L L P NC lifted its holdings in Thermo Fisher Scientific by 8.3% in the 3rd quarter. Wedge Capital Management L L P NC now owns 740 shares of the medical research company’s stock worth $375,000 after purchasing an additional 57 shares in the last quarter. Summit Global Investments raised its holdings in shares of Thermo Fisher Scientific by 27.8% during the 3rd quarter. Summit Global Investments now owns 1,392 shares of the medical research company’s stock worth $704,000 after acquiring an additional 303 shares in the last quarter. Finally, Naples Global Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 37.3% during the 3rd quarter. Naples Global Advisors LLC now owns 755 shares of the medical research company’s stock worth $382,000 after acquiring an additional 205 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $548.37 on Tuesday. The stock’s fifty day moving average is $571.30 and its two-hundred day moving average is $528.18. The company has a market capitalization of $209.32 billion, a PE ratio of 35.49, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same period in the prior year, the business earned $5.40 EPS. The business’s revenue for the quarter was down 4.9% compared to the same quarter last year. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on TMO shares. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. HSBC upped their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Raymond James boosted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Finally, Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $604.69.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.